COMPANY

Clear Scientific, Inc.

HQ: Cambridge, MA source · clearsci.com ↗ · New England

Also known as Clear Scientific · 20 sources

Keywords: neurology metabolic metabolic diseases Methamphetamine Intoxication Methamphetamine Abuse Fentanyl Overdose Fentanyl Poisoning Methamphetamine Disorders Substance Use Disorders CS-1103

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)14NIH grants

Funding and NIH signals

NIH award NIH awarded $3M (NIH grant 1U01DA066075-01, new, notice Jul 20, 2026). NIH RePORTER 1U01DA066075-01 (Jul 20, 2026)
Evidence (1 event)
- Jul 20, 2026 · NIH RePORTER 1U01DA066075-01
  Organization: CLEAR SCIENTIFIC, LLC; City/State: CAMBRIDGE, MA; Project number: 1U01DA066075-01; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 3000030; Administering IC: National Institute on Drug Abuse; Project title: A Phase 2a clinical study to evaluate the safety and efficacy of CS-1103, a therapeutic agent to treat methamphetamine intoxication; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 20, 2026 Grant Government grant — NIH U01: $3M (annual award, as published), announced Jul 20, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
May 28, 2026 Trial start 2: A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade source ↗
Feb 5, 2026 Trial start Phase 2: A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine source ↗
Jul 24, 2025 Grant Government grant — SBIR: $1.54M (annual award, as published), announced Jul 24, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Jul 16, 2025 Grant Government grant — NIH U01: $3.8M (annual award, as published), announced Jul 16, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Feb 7, 2024 Trial start Phase 1: A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants source ↗

Funding

Last 2 years.

Jul 20, 2026 Government grant — NIH U01: $3M (annual award, as published), announced Jul 20, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Jul 24, 2025 Government grant — SBIR: $1.54M (annual award, as published), announced Jul 24, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Jul 16, 2025 Government grant — NIH U01: $3.8M (annual award, as published), announced Jul 16, 2025. Agency: NIH/NIDA. Source: government award database. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07459166	A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade	2	Recruiting	May 28, 2026	Jul 22, 2026 (actual)
NCT06721494	A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine	Phase 2	Recruiting	Feb 5, 2026	Sep 4, 2026 (estimated)
NCT06316973	A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants	Phase 1	Completed	Feb 7, 2024	May 30, 2024 (actual)

NIH awards 14

Annual award amounts. Total $31.2M.

Aug 28, 2024 NIH award 5U01DA058548-02 FY2024: $4,092,920 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Clinical Development of a Therapeutic Ag source ↗
Aug 6, 2024 NIH award 5UG3DA059286-02 FY2024: $3,051,790 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. A Therapeutic Agent to Lower the Level o source ↗
Aug 1, 2024 NIH award 2R44DA056272-02 FY2024: $1,462,687 awarded for that fiscal year; activity R44 (SBIR); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. A Novel Reversal Agent for Treatment of Overd source ↗
Aug 22, 2023 NIH award 1UG3DA059286-01 FY2023: $3,035,865 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. A Therapeutic Agent to Lower the Level o source ↗
Aug 15, 2023 NIH award 1U01DA058548-01 FY2023: $4,069,920 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Clinical Development of a Therapeutic Ag source ↗
Sep 22, 2022 NIH award 1R43DA057782-01 FY2022: $319,946 awarded for that fiscal year; activity R43 (SBIR); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. An oral therapeutic to treat intoxication by pr source ↗
Aug 24, 2022 NIH award 5R44DA052957-03 FY2022: $1,245,607 awarded for that fiscal year; activity R44 (SBIR); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Novel Therapeutic Agents to Reverse Opioid Ov source ↗
Jun 23, 2022 NIH award 1R43DA056272-01 FY2022: $319,695 awarded for that fiscal year; activity R43 (SBIR); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. A novel therapeutic approach for treatment of a source ↗
Jun 16, 2022 NIH award 5U01DA053054-03 FY2022: $4,067,228 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Therapeutic Agent for Rapid Reversal of source ↗
Sep 22, 2021 NIH award 2R44DA052957-02 FY2021: $1,283,728 awarded for that fiscal year; activity R44 (SBIR); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Novel Therapeutic Agents to Reverse Opioid Ov source ↗
Sep 20, 2021 NIH award 3U01DA053054-02S1 FY2021: $114,933 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Evaluation of the drug-drug interactions source ↗
Jun 9, 2021 NIH award 5U01DA053054-02 FY2021: $3,941,786 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Therapeutic Agent for Rapid Reversal of source ↗
Sep 22, 2020 NIH award 1U01DA053054-01 FY2020: $3,932,236 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Therapeutic Agent for Rapid Reversal of source ↗
Sep 21, 2020 NIH award 1R43DA052957-01 FY2020: $224,889 awarded for that fiscal year; activity R43 (SBIR); PI LI, XINHUA; recipient as written: CLEAR SCIENTIFIC, LLC, CAMBRIDGE, MA. Novel Therapeutic Agents to Reverse Opioid Over source ↗